PepGen to Participate in the SVB Securities Global Biopharma Conference

Rhea-AI Summary

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, Ph.D., will present at the SVB Securities’ Global Biopharma Virtual Conference on February 16, 2023, at 10:40 A.M. EST. The presentation aims to highlight PepGen's next-generation oligonucleotide therapies designed to transform treatment for severe neuromuscular and neurological diseases.

The event will be available for live streaming, and a replay will be accessible on PepGen's website for 90 days afterward. The company focuses on enhancing the delivery of oligonucleotide therapeutics through its Enhanced Delivery Oligonucleotide (EDO) platform.

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at SVB Securities’ Global Biopharma Virtual Conference on Thursday, February 16^th 2023, at 10:40 A.M. EST.

The live webcast corporate presentation may be accessed under Events and Presentations in the Investor Relations section of PepGen’s website. A replay of the webcast will be available on the website for 90 days following the presentation.

About PepGen

PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.

Investor Contact
Laurence Watts
Gilmartin Group
Laurence@gilmartinir.com  

Media Contact
Gwendolyn Schanker
LifeSci Communications
gschanker@lifescicomms.com

FAQ

When is PepGen's presentation at the SVB Securities Global Biopharma Virtual Conference?

PepGen's presentation is scheduled for February 16, 2023, at 10:40 A.M. EST.

Who will be presenting for PepGen at the upcoming conference?

James McArthur, Ph.D., President and CEO of PepGen, will be the presenter.

How can I access PepGen's conference presentation?

The live webcast can be accessed through the Investor Relations section of PepGen's website.

Will there be a replay of PepGen's conference presentation?

Yes, a replay will be available on PepGen's website for 90 days after the presentation.

What is the focus of PepGen's research and therapies?

PepGen focuses on advancing oligonucleotide therapies for severe neuromuscular and neurological diseases.

What platform does PepGen use for its oligonucleotide therapies?

PepGen utilizes the Enhanced Delivery Oligonucleotide (EDO) platform to enhance therapeutic delivery.